Overall verdict
Buy
6.8/10
1-year performance
-53.60%
Score breakdown
Down 53.6% over 1 year, 3% of the 52-week range.
Strongest: Profitability 8.8/10. Weakest: Shareholder return 2.7/10.
31 analysts, target +0.4% vs the price.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products ;
devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems ; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart ; WATCHMAN FLX, a left atrial appendage closure (LAAC) device ; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.
In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Michael Mahoney
Founded
1979
Employees
59 000
Revenue / employee
340 237 USD
Next earnings
October 28, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.8.88%
- VANGUARD CAPITAL MANAGEMENT LLC6.65%
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM6.64%
- STATE STREET CORP4.80%
- PRIMECAP MANAGEMENT CO/CA/3.46%
- FMR LLC3.13%
- GEODE CAPITAL MANAGEMENT, LLC2.29%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.04%
- D. E. Shaw & Co., Inc.1.74%
- Other institutions57.83%
- Rest of the register2.54%
1470 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
105.65 USD
52-week low
42.20 USD
1-year performance
-53.60%
Declining
Year-to-date performance
-53.38%
Declining
Drawdown
-58.09%
Major drawdown
Position in the 52-week range
3% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 2.1 times harder.
10,000 € placed at the end of September 2009 are worth today
| Boston Scientific | 57 336 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.1 times as much as the world ETF.
- Worst fall:-64 % between February 2025 and July 2026. 10,000 € placed at the top fell to 3 623 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Boston Scientific earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Boston Scientific: 57 336 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 54.48 USD - 56.83 USD (3 methods agree)
The price implies growth of 3.50% per year; the company grows at 15.16%.
Gross margin 66.4%, net margin 17.5%, ROIC 10.5%, ROE 15.5%.
Net margin
17.50%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
66.36%
Fair
Return on equity (ROE)
15.52%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
10.53%
Exceptional
Free cash flow margin (FCF)
17.27%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.99x
Fair
Margin stability
12.0 pts
Very uneven
Revenue to net income
Growth
6.8/10Revenue up 7.5% over 1 year, 15.2% a year over 5.
Revenue (trailing 12 months)
21.0Md USD
Revenue growth (1y)
7.53%
Solid
Revenue growth (3y)
58.29%
Strong
EPS growth (1y)
15.25%
Strong
EPS CAGR (5y)
—
EPS revisions (3 months)
-2.73%
Revised down
Valuation
8.3/10P/E 18.0x, forward P/E 16.7x, EV/EBITDA 13.5x, PEG 0.39. The multiple sits in the 3th percentile of its own 5-year history.
P/E (TTM)
18.0x
Fair
Sector 29.3x|S&P 23.0x
Forward P/E
16.7x
Fair
EV / EBITDA
13.5x
Fair
Sector 16.0x|S&P 14.5x
PEG
0.39
Growth unpriced
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
55.65 USD
Undervalued
P/E vs its own 5-year history
among the 3% lowest valuations
Far cheaper than usual
Market cap
64.7Md USD
Financial strength
6.6/10Cash covers 5.1% of the debt, net debt/EBITDA 1.8x.
Net debt / EBITDA
1.8x
Tight
Gearing (net debt / equity)
47.58%
Solid
Cash
648M USD
Cash / market cap
1.00%
Stretched
Cash / total debt
5.13%
Stretched
Interest coverage
11.4x
Very solid
Net debt
12.0Md USD
Equity
25.2Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 44.68 USD
- MM2045.33
- MM5046.89
- MM20063.20
- RSI 1444.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-8.32%
200-day average slope, 3 months
-20.94%
50-day average slope, 1 month
+0.82%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
2.46 % per day
Volatility change
-1.16%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.64 (9) | 3.27 (25) | 21 279 (27) | 6 527 (14) | 3 787 (9) |
| 2027 | 2.52 (10) | 3.41 (26) | 22 258 (28) | 6 780 (14) | 3 670 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 2 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 3 | BSX | 6.8 | 7.3 | 64.7Md USD | 18.0x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -53.6 % | ||
| 4 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
